Trials / Active Not Recruiting
Active Not RecruitingNCT07298538
Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer
Long-term Survival of Unresectable Hepatocellular Carcinoma Patients Receiving Lenvatinib-based Therapy: A Retrospective, Multicenter Propensity Score Matching Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study reviewed real-world outcomes of patients with unresectable hepatocellular carcinoma who received lenvatinib-based treatment. The study evaluated long-term survival, treatment response, and safety using data collected from six hospitals.
Conditions
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2025-12-01
- Completion
- 2027-12-01
- First posted
- 2025-12-23
- Last updated
- 2025-12-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07298538. Inclusion in this directory is not an endorsement.